Actively Recruiting
Naringenin Supplementation in Bone Fracture Patients
Led by Shahid Beheshti University of Medical Sciences · Updated on 2026-02-24
70
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and impaired physical functioning. The occurrence of surgical site infections (SSI) represents a significant threat to the efficacy of osteosynthesis procedures. As with other traumas and surgical procedures, the secretion of inflammatory mediators is markedly elevated in this cohort of patients following surgery. Naringenin is one of the most prevalent flavonoids, occurring naturally in grapefruit and other citrus fruits. In vitro studies have demonstrated that naringenin may stimulate the release of osteogenic cytokines and suppress the production of pro-inflammatory factors, which can result in a reduction in bone resorption. Based on these findings, naringenin may prove an effective agent for accelerating the rate of fusion and controlling inflammation. Furthermore, it may enhance quality of life and augment functional activity.
CONDITIONS
Official Title
Naringenin Supplementation in Bone Fracture Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 60 years
- Candidate for orthopedic surgery for bone fractures of the lower limbs
- Ambulatory without assistance for at least two months before the fracture
- No amputation of the lower limbs
- No liver cirrhosis
- No advanced kidney failure (blood creatinine ≤ 1.4 mg/dL)
- No metastatic cancer
- No chronic inflammatory diseases
- Not taking drugs that affect bone metabolism, including calcitonin, bisphosphonates, and corticosteroids
- Not taking anti-inflammatory drugs
You will not qualify if you...
- Allergy or intolerance to naringenin capsules
- Abnormal changes in liver or kidney tests
- Failure to consume more than 90% of assigned capsules during weekly monitoring
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ayatollah Taleghani Educational Hospital
Tehran, Iran
Actively Recruiting
Research Team
F
Faeze Gohari, M.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here